ArticleBMC cancer2022
Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The Regulation of Vasomotor and Cardiorespiratory Pulsations Is Disrupted in Primary Central Nervous System Lymphoma: A Case-Control fMRI Study.Human brain mapping · 2026Article
- Educational and regional differences in population-based incidence and survival of primary central nervous system lymphoma in Finland.BMC cancer · 2026Article
- Article
- Population based registry study on large B-cell lymphoma mortality and morbidity in Finland.Acta oncologica (Stockholm, Sweden) · 2025Article
- Defining MRI-based follow-up protocol for primary central nervous system lymphoma.Annals of hematology · 2025Article
- Vasomotor fluctuations are increased in primary central nervous system lymphoma: a case-control study with fast functional MRI.Brain communications · 2025Article
- Accuracy of Intra-Axial Brain Tumor Characterization in the Emergency MRI Reports: A Retrospective Human Performance Benchmarking Pilot Study.Diagnostics (Basel, Switzerland) · 2024Article
- Primary Central Nervous System Lymphoma Presenting as a Solitary Fourth Ventricular Mass: A Case Report.Cureus · 2024Article
- Extranodal lymphoma: pathogenesis, diagnosis and treatment.Molecular biomedicine · 2023Review
- Primary central nervous system lymphoma.Nature reviews. Disease primers · 2023Review
- Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry.Annals of hematology · 2023Article
- Improving the Classification of PCNSL and Brain Metastases by Developing a Machine Learning Model Based onJournal of personalized medicine · 2023Article
- Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe report here the first population-based incidence rates and prognosis of primary central nervous system lymphoma (PCNSL) in Finland.
methodsFinnish Cancer Registry data by histological diagnosis and tumor location (2007-2017) for cases with diffuse large B-cell lymphoma.
resultsDuring 2007-2017, 392 new cases of PCNSL were reported (195 males, 197 females). The average age-adjusted incidence was 0.68/100,000 person-years. Incidence for males was 0.74/100,000 and for females 0.63/100,000, respectively. The incidence was highest, 2.93/100,000, among people aged 75-79 years. Concerning all cases in 2007-2017 the 2-year age-adjusted relative survival rate was 33% and the corresponding 5-year survival rate was 26%. Among patients under the age of 70, the age-adjusted 5-year relative survival rate increased from 36% in 2007-2012 to 43% for 2013-2017. Among patients aged 70+ the corresponding survival rates were poor, 7 and 9%.
conclusionsPCNSL incidence in Finland is among the highest reported in the world. The annual increase in incidence was 2.4%. The prognosis is still dismal, especially in elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.